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Abstract 
Pneumocystis jirovecii is an important cause of interstitial pneumonia particularly among 
immunocompromised hosts. We analyzed the prevalence of P. jirovecii pneumonia (PCP) among 
HIV-infected and HIV-uninfected patients presented with interstitial pneumonia or acute 
respiratory syndrome hospitalized in six Croatian tertiary care hospitals. Over four-year period 
(2010-2013), a total of 328 lower respiratory tract samples: 253 (77.1%) bronchoalveolar lavage 
fluid, 43 (13.1%) tracheal aspirates and 32 (9.8%) bronchial aspirates from 290 patients were 
examined by real-time polymerase chain reaction (PCR). PCP was detected in 23 (7.9%) patients. 
The prevalence of PCP differed significantly among tested groups (χ
2
=95.03; d.f. =3; p<0.001). 
HIV-infected patients were more often positive (56.6%, 95%CI=37.3-72.4) compared to other 
groups (patients with malignant disease 7.7%, 95%CI=2.6-20.3; transplant patients 7.7%, 
95%CI=2.2-24.1; patients with other diagnosis 1.5%, 95%CI=0.5-4.4). Majority of HIV-positive 
patients (80%) were newly diagnosed cases. Our results indicate that HIV-infected patients still 
represents the main risk group for P. jirovecii infection. PCP is responsible for pneumonia in 56.6% 
HIV-positive patients in Croatia, primarily those who do not know that they are HIV infected.  
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Introduction 
Pneumocystis jirovecii is an opportunistic fungal pathogen causing human pneumocystis 
pneumonia (PCP) [1]. PCP remains a major cause of morbidity and mortality in patients with 
compromised immune system caused by HIV, chemotherapeutic regimens for malignancies and 
immunosuppressive therapy after organ transplantation. However, any patient with an impaired 
immunity such as those receiving corticosteroids for autoimune diseases or other 
immunosupressive medications are also at significant risk  [2]. PCP is still a frequent AIDS-
defining opportunistic infection [3, 4]. Without specific prophylaxis, 60-80% of HIV-infected 
individuals will develop PCP during the course of their illness [5]. 
Pneumocystis cannot be cultured. The diagnosis is based on direct microscopic examination using 
staining techniques (methenamine silver and modified Giemsa stain). Immunofluorescent staining 
with monoclonal antibodies and molecular methods (conventional polymerase-chain reaction-PCR 
or real-time PCR) are more sensitive [6, 7]. 
There has been lack of epidemiological studies on the occurrence of PCP in Croatia so far. The aim 
of this study was to analyze the prevalence of PCP among HIV- infected and HIV-uninfected 
patients hospitalized with clinical and radiologic findings of interstitial pneumonia. 
Patients and methods 
Patients 
Over a four-year period (2010-2013), a total of 328 samples: 253 (77.1%) broncho-alveolar lavage 
fluids (BAL), 43 (13.1%) tracheal aspirates (TA) and 32 (9.8%) bronchial aspirates (BA) were 
tested for P.jirovecii using real-time PCR. Samples were collected from 290 hospitalized patients 
presented with interstitial pneumonia or acute respiratory syndrome in six tertiary care hospitals in 
Croatia. Two hundred and seventy-seven samples were additionally tested using IFA. There were 
190 (65.5%) males and 100 (34.5%) females, aged from 6 months to 73 years. Twenty-seven were 
  
HIV-infected and 263 HIV- uninfected.  Among HIV-uninfected patients, 39 (14.8%) had 
malignant disease and 26 (9.9%) were transplant patients. The majority of the remaining 198 
(75.3%) patients had no clear evidence of predisposing immunodeficiency.  
Methods 
Real-time PCR was performed using an ABI 7500 sequence detector system (Applied Biosystems, 
Foster City, CA).  DNA was extracted using an automatic vacuum extraction method QIA extractor 
(Qiagen, Germany) according to the manufacturer's protocol. Primers and probe for amplification 
were designed with the Primer Express software (Applied Biosystems, Foster City, CA) in order to 
specifically amplify the P. jiroveci beta-tubulin gene (Genbank accession no. AF170964) - the 
forward primer (1186F-52GATCCGAGACATGGTCGCTATT), reverse primer (1257R-
52TTCAACCTCCTTCATGGAAACAG) and TaqMan probe (1212T-
52TGTTGCAGCGATTTTCCGCGGTA).  The specimen was considered positive if the results 
exceeded the threshold with the Ct values < 40 cycles.  To detect samples containing PCR 
inhibitors, an internal positive control (IPC) (TaqMan Exogenous Internal Positive Control, 
Applied Biosystems, Foster City, CA) was used. A negative result for the target and a positive 
result for the IPC DNA indicate that no target sequence is present. A negative result for each 
suggests PCR inhibition [8]. Indirect immunofluorescence assay (IFA) was performed using a 
commercial test (MONOFLUO Pneumocystis jirovecii IFA test kit, Bio-Rad, Marnes la Coquette, 
France). 
Statistical analysis: Prevalence of Pneumocystis jirovecii pneumonia in Croatian patients by 
underlying diseases is expressed with associated confidence intervals and the chi-squared test 
was used to compare differences between groups. Statistical analyses were performed using 
MedCalc for WINDOWS version 7.0. P<0.05 was considered to be statistically significant. 
  
Results 
P. jirovecii was detected in 23 (7.9%) patients. The prevalence of PCP differed significantly 
among tested groups (χ
2
=95.03; d.f. = 3; p<0.001). The highest prevalence (15/27; 56.6%; 
95%CI=37.3-72.4) was documented in HIV-positive patients. PCP occurred with equal frequency 
in patients with malignant disease (3/39; 7.7%; 95%CI=2.6-20.3) and transplant patients (2/26; 
7.7%, 95%CI=2.2-24.1).  The lowest prevalence (3/1.5%, 95%CI=0.5-4.4) was reported in the 
group of 198 patients without clearly defined immunodeficiency (Table 1). 
Demographic, clinical and laboratory data of 23 P.jirovecii positive patients are presented in the 
table 2. Majority of HIV-positive patients (15/19; 80%) were newly diagnosed patients. Of seven 
HIV-uninfected patients, there were three patients with hematological malignancy and three 
patients with transplant kidney. Six of P.jirovecii positive patients died (Table 2). 
Thirty of 328 (9.1%) of samples tested positive for P. jirovecii using PCR: 26/253 (10.3%) BAL 
3/32 (9.4%) BA and 1/43 (2.3%) TA. IFA was positive in 21/217 (9.7%) BAL and 1/30 (3.3%)  
BA samples.   
Disscusion 
Despite a decline in the incidence of PCP in the era of highly active antiretroviral therapy 
(HAART), it remains a frequent and serious opportunistic disease in HIV-infected patients [4]. In 
2008, World Health Organization reported that PCP was the leading AIDS-indicator disease 
accounting for 16.4% of the AIDS cases diagnosed in adults and adolescents that year [9]. The 
incidence of PCP in low- and middle- income countries differed from that in the developed world  
[10]. In developed countries, the incidence has declined owing to the routine use of HAART and 
cotrimoxazole prophylaxis [11]. People who live in developing countries continue to be 
devastated by HIV and PCP occurs frequently. Data from Central and South America showed 
  
PCP prevalence in HIV-infected patients between 24% and 55% [10]. Clinical studies from 
Africa in HIV-infected patients with pneumonia report that PCP accounted for 0.8 to 38.6% of 
cases [12, 13]. The apparently lower prevalence of PCP in Africa may be explained in part by 
early mortality from other infections such as tuberculosis or bacterial pneumonia and possibly 
also due to the lack of sensitive diagnostic methods [14]. In contrast, in some other resource-
limited countries such as India, PCP appears to occur more frequent (45.2%)  [15]. 
The prevalence of PCP pneumonia in Croatian HIV-infected patients (57.7%) was comparable to 
that recorded in some developing countries such as Thailand (57%)  [16], Malaysia (62.7%)  [17] 
and Vietnam (55%) [18].Some developed countries such as China, reported even higher 
prevalence of PCP (70.22%)  [19].In this study, the prevalence of HIV-infected patients was 
significantly higher prevalence of PCP compared to other groups. PCP pneumonia occurs 
primarily among HIV-positive persons who were not receiving antiretroviral therapy or PCP 
prophylaxis, and many were unaware of their HIV infection at the time of presentation [20].  
Majority of patients in this study (80%) were newly diagnosed cases.  
In the last decade, P.jirovecii infections are becoming increasingly recognized in non-HIV 
immunosuppressed patients [21-24]. Our results showed that 7.7% transplant patients were 
positive for P.jirovecii. A Spanish study detected P.jirovecii in 15% solid organ transplants [25] 
while in two French studies, solid organ transplant recipients accounted for 17.4% [26] and 7.0%  
[27] of PCP among HIV-negative patients. Lower prevalence rate (2.2%) was reported in 
Slovenian kidney transplant recipients [28]. 
Patients with cancer are another group with substantial risk for P.jirovecii infection. In patients 
with hematological malignancies, PCP prevalence rates ranging from 8.4% to 10% [29, 30] were 
reported. A similar rate of PCP in patients with malignant disease (7.7%) was found in this study. 
The lowest prevalence rate of PCP (1.5%) was detected in patients without clear predisposing 
  
immunodeficiency. Comparing PCR to IFA results, the real-time PCR assay was more sensitive  
for the detection of P. jirovecii from all tested clinical samples like in other similar sudies [6, 7] . 
Our study has some limitations. In addition to a limited number of patients in each risk group, 
some of data on the possible underlying disease were incomplete. 
Despite these limitations, the results of this first Croatian prevalence study showed that HIV-
infected persons still represents the main risk group for P. jirovecii infection. PCP was detected in 
56.6% HIV-positive patients, primarily those who do not know that they are HIV infected.  
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Table 1. Prevalence of Pneumocystis jirovecii pneumonia in Croatian patients (2010-2013) 
Underlying disease Tested 
N (%) 
PCR positive 
N (%) 
95%CI 
HIV-infected 27 (9.3%) 15 (56.6%)      37.3 - 72.4 
Malignant disease 39 (13,5%) 3 (7.7%) 2.6 - 20.3 
Transplant organ 26 (9.0%) 2 (7.7%) 2.2 - 24.1 
Pneumonia, ARDS 198 (68,2%) 3 (1.5%) 0.5 - 4.4 
TOTAL 290 (100%) 23 (7.9%)  
χ
2
=95.03; d.f.=3; p=<0.001 
 
Table 2. Demographic, clinical and laboratory data of 23 patients with Pneumocystis jirovecii pneumonia 
Case Age Gender Sample PCR IFA Underlying disease Outcome 
1 39 M BAL Positive Positive HIV Died 
2 50 M BAL Positive Positive HIV Died 
3 53 M BA Positive Positive HIV Died 
4 64 F BAL Positive Negative HIV  
5 1 M BAL Positive Positive 
a
SCID  
6 2 M BAL Positive Positive Malignant disease Died 
7 47 M BAL Positive Positive Kidney transplant  
8 63 M BAL Positive Positive Kidney transplant  
9 34 M BAL Positive Positive HIV  
10 0.6 M BAL Positive Positive HIV  
11 23 M BA Positive Negative HIV  
12 58 M BAL Positive Positive HIV Died 
13 23 M BA Positive Negative HIV  
14 30 M BAL Positive Positive HIV  
15 53 M TA Positive Negative HIV  
16 73 F BAL Positive Positive Tuberculosis  
17 49 M BAL Positive Positive HIV  
18 55 M BAL Positive Positive Brain abscess Died 
19 4 M BAL Positive Positive Malignant disease  
20 41 F BAL Positive 
b
NT HIV  
21 47 F BAL Positive 
b
NT HIV  
22 38 M BAL Positive 
b
NT HIV  
23 68 M BAL Positive 
b
NT cNHL  
 
a
SCID = severe combined immunodeficiency 
b
NT   =   not tested 
c
NHL = non-Hodgkin lymphoma 
